No study has compared sexual functioning and depressive symptoms in male subjects with various types of prediabetes. Our study included four age- and weight-matched groups of apparently healthy men (25–50 years old): subjects with isolated impaired fasting glucose (IFG) (n = 16), men with isolated impaired glucose tolerance (n = 17), individuals with the presence of both IFG and impaired glucose tolerance (n = 16), as well as men with normal glucose tolerance (n = 18). All included men completed questionnaires evaluating male sexual functioning (IIEF-15) and assessing the presence and severity of depressive symptoms (BDI-II). Men with both IFG and impaired glucose tolerance obtained lower domain scores for erectile function, sexual desire, and overall satisfaction, as well as the higher overall BDI-II score. Individuals with isolated impaired glucose tolerance (IGT) and IFG were characterized by lower domain score only for sexual desire. In all study groups, domain score for erectile function correlated with the BDI-II score, while scores for erectile function and sexual desire correlated with a degree of insulin resistance. The obtained results suggest that prediabetes may impair sexual functioning in young men. The risk is particularly high in individuals with the presence of both IFG and IGT.
Subscribe to Journal
Get full journal access for 1 year
only $14.88 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61.
Giuliano FA, Leriche A, Jaudinot EO, de Gendre AS. Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both. Urology. 2004;64:1196–201.
Moreira ED Jr., Lbo CF, Diament A, Nicolosi A, Glasser DB. Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology. 2003;61:431–6.
Fedele D, Bortolotti A, Coscelli C, Santeusanio F, Chatenoud L, Colli E, et al. Erectile dysfunction in type1 and type 2 diabetics in Italy. On behalf of Gruppo Italiano Studio Deficit Erettile nei Diabetici. Int J Epidemiol. 2000;29:524–31.
Bacon CG, Hu FB, Giovannucci E, Glasser DB, Mittleman MA, Rimm EB. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care. 2002;25:1458–63.
De Berardis G, Pellegrini F, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S, et al. Clinical and psychological predictors of incidence of self-reported erectile dysfunction in patients with type 2 diabetes. J Urol. 2007;177:252–7.
Rabijewski M, Papierska L, Kuczerowski R, Piątkiewicz P. Hormonal determinants of erectile dysfunction and lower urinary tract symptoms in middle-aged and elderly men with prediabetes. Aging Male. 2015;18:256–64.
Corona G, Rastrelli G, Balercia G, Lotti F, Sforza A, Monami M, et al. Hormonal association and sexual dysfunction in patients with impaired fasting glucose: a cross-sectional and longitudinal study. J Sex Med. 2012;9:1669–80.
Grover SA, Lowensteyn I, Kaouache M, Marchand S, Coupal L, DeCarolis E, et al. The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. Arch Intern Med. 2006;166:213–9.
Maseroli E, Corona G, Rastrelli G, Lotti F, Cipriani S, Forti G, et al. Prevalence of endocrine and metabolic disorders in subjects with erectile dysfunction: a comparative study. J Sex Med. 2015;12:956–65.
Ettala OO, Korhonen PE, Syvänen KT, Kaipia AJ, Vahlberg TJ, Aarnio PT, et al. Erectile dysfunction cannot be used in primary screening of prediabetes. Diabetes Res Clin Pract. 2015;108:e60–e62.
Krysiak R, Drosdzol-Cop A, Skrzypulec-Plinta V, Okopień B. Sexual functioning and depressive symptoms in women with diabetes and prediabetes receiving metformin therapy: a pilot study. Exp Clin Endocrinol Diabetes. 2017;125:42–48.
Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR, Australian Diabetes Society; Australian Diabetes Educators Association. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust. 2007;186:461–5.
Petersen JL, McGuire DK. Impaired glucose tolerance and impaired fasting glucose - a review of diagnosis, clinical implications and management. Diab Vasc Dis Res. 2005;2:9–15.
Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006;29:1130–9.
DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance andimpaired fasting glucose. Am J Cardiol. 2011;108(Suppl. 3):3B–24B.
Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes. 1997;46:701–10.
Vaccaro O, Ruffa G, Imperatore G, Iovino V, Rivellese AA, Riccardi G. Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis. Diabetes Care. 1999;22:1490–3.
Krysiak R, Szkróbka W, Okopień B. The effect of l-thyroxine treatment on sexual function and depressive symptoms in men with autoimmune hypothyroidism. Pharmacol Rep. 2017;69:432–7.
Rosen RC, Cappelleri JC, Gendrano N 3rd. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res. 2002;14:226–44.
Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology. 1999;54:346–51.
Beck AT, Steer RA, Brown GK BDI-II: Beck Depression Inventory Manual. Edn 2. Psychological Corporation, San Antonio, 1996.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders—DSM-IV-TR. Edn 4. Washington: American Psychiatric Publishing; 1994.
Zawadzki B, Popiel A, Praglowska E, Psychometric properties of the polish version of the Aaron T. Beck’s depression inventory BDI-II. Psychol Etol Genet. 2009;19:71–95.
Corona G, Isidori AM, Aversa A, Burnett AL, Maggi M. Endocrinologic control of men’s sexual desire and arousal/erection. J Sex Med. 2016;13:317–37.
Cunningham GR. Testosterone and metabolic syndrome. Asian J Androl. 2015;17:192–6.
Arthur R, Rohrmann S, Møller H, Selvin E, Dobs AS, Kanarek N, et al. Pre-diabetes and serum sex steroid hormones among US men. Andrology. 2017;5:49–57.
Kher N, Marsh JD. Pathobiology of atherosclerosis - a brief review. Semin Thromb Hemost. 2004;30:665–72.
Krysiak R, Okopień B. The effect of fenofibrate on lymphocyte cytokine release in patients with impaired fasting glucose and impaired glucose tolerance: a preliminary report. Atherosclerosis. 2010;213:325–8.
Krysiak R, Gdula-Dymek A, Bachowski R, Okopień B. Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of prediabetes. Diabetes Care. 2010;34:2266–70.
Dimova R, Tankova T, Guergueltcheva V, Tournev I, Chakarova N, Grozeva G, et al. Risk factors for autonomic and somatic nerve dysfunction in different stages of glucose tolerance. J Diabetes Complicat. 2017;31:537–43.
Cortez M, Singleton JR, Smith AG. Glucose intolerance, metabolic syndrome, and neuropathy. Handb Clin Neurol. 2014;126:109–22.
Pedro-Botet J, Flores-Le Roux JA, Mostaza JM, Pintó X, de la Cruz JJ, Banegas JR. Atherogenic dyslipidemia: prevalence and management in lipid clinics. Rev Clin Esp. 2014;214:491–8.
Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
Aroda VR, Knowler WC, Crandall JP, Perreault L, Edelstein SL, Jeffries SL, et al. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia. 2017;60:1601–11.
Krysiak R, Drosdzol-Cop A, Skrzypulec-Plinta V, Okopień B Sexual functioning and depressive symptoms in women with various types of prediabetes: a pilot study. Endokrynol Pol 2018;69:175–81. [in press].
Zunszain PA, Hepgul N, Pariante CM. Inflammation and depression. Curr Top Behav Neurosci. 2013;14:135–51.
Conflict of interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Krysiak, R., Szkróbka, W. & Okopień, B. Sexual functioning and depressive symptoms in men with various types of prediabetes: a pilot study. Int J Impot Res 30, 327–334 (2018). https://doi.org/10.1038/s41443-018-0050-6